U.S. License Holder:
Pfizer Inc.
Date of License:
August-14-2023
Last Update:
Dec-15-2024
FDA-Approved Indications
ELREXFIO (elranatamab) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.